Signals, Powered By EquityPandit
The US health regulator USFDA has issued a warning letter to the Hyderabad based Vista Pharmaceuticals over a significant violations of good manufacturing norms at its Nalgonda facility in Telangana.
The US Food and Drug Administration (USFDA) has said that the warning letter was issued to the company after finding various non-compliance of norms, including failure to clean, sanitise and sterilise equipment and utensils used in manufacturing drugs, during an inspection of the facility from September 19 to 23, 2016.
The USFDA, in its letter to Vista Pharmaceuticals Managing Director Dhananjaya Alli, said that “Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated.”
